This site is intended for healthcare professionals
Drug news

Phase III data on Kovaltry (recombinant Factor VIII) in haemophilia published online- Bayer HealthCare

Read time: 1 mins
Last updated:12th Dec 2015
Published:12th Dec 2015
Source: Pharmawand

New Phase III data from Bayer HealthCare's LEOPOLD Kids clinical trial investigating the safety and efficacy of BAY 81-8973, otherwise known as Kovaltry (recombinant Factor VIII) in previously treated children were published online in Haemophilia, the official peer-reviewed journal of the World Federation of Hemophilia. LEOPOLD Kids is a two-part, open-label, non-randomized phase III study.

Part A was designed to evaluate the efficacy and safety of BAY 81-8973 for prophylaxis, treatment of bleeds, and surgical management in previously treated children 12 years of age and younger, using regimens of two times or three times per week or every other day. Part B of the study, which involves previously untreated patients (PUPs), is ongoing. Bayer has submitted marketing applications for BAY 81-8973 in several countries, including the USA.

See: BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.